Insider Transactions in Q1 2025 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
530
-0.9%
|
$251,750
$475.34 P/Share
|
|
Feb 27
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
2,650
-12.04%
|
$1,258,750
$475.34 P/Share
|
|
Feb 27
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,272
-3.71%
|
$610,560
$480.0 P/Share
|
|
Feb 26
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,962
-8.28%
|
$2,376,798
$479.61 P/Share
|
|
Feb 26
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
3,703
-5.13%
|
$1,773,737
$479.61 P/Share
|
|
Feb 26
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,962
-7.75%
|
$2,376,798
$479.61 P/Share
|
|
Feb 26
2025
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,962
-13.19%
|
$2,376,798
$479.61 P/Share
|
|
Feb 26
2025
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
14,079
-11.73%
|
$6,743,841
$479.61 P/Share
|
|
Feb 26
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,482
-10.14%
|
$1,188,878
$479.61 P/Share
|
|
Feb 26
2025
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,071
-10.1%
|
$3,387,009
$479.61 P/Share
|
|
Feb 26
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,241
-13.66%
|
$594,439
$479.61 P/Share
|
|
Feb 26
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,954
-14.81%
|
$2,851,966
$479.61 P/Share
|
|
Feb 25
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
354
-0.55%
|
$169,920
$480.95 P/Share
|
|
Feb 25
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
848
-2.07%
|
$407,040
$480.95 P/Share
|
|
Feb 25
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
884
-8.87%
|
$424,320
$480.95 P/Share
|
|
Feb 25
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
1,767
-6.73%
|
$848,160
$480.95 P/Share
|
|
Feb 24
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,310
-4.89%
|
$1,598,730
$483.28 P/Share
|
|
Feb 24
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,310
-5.23%
|
$1,598,730
$483.28 P/Share
|
|
Feb 24
2025
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,310
-8.08%
|
$1,598,730
$483.28 P/Share
|
|
Feb 24
2025
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,386
-7.25%
|
$4,533,438
$483.28 P/Share
|
|
Feb 24
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,470
-3.31%
|
$1,193,010
$483.28 P/Share
|
|
Feb 24
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,971
-8.82%
|
$1,917,993
$483.28 P/Share
|
|
Feb 24
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
828
-7.67%
|
$399,924
$483.28 P/Share
|
|
Feb 24
2025
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,716
-6.31%
|
$2,277,828
$483.28 P/Share
|
|
Feb 24
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,656
-5.93%
|
$799,848
$483.28 P/Share
|
|
Feb 20
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,111
-2.41%
|
$533,280
$480.0 P/Share
|
|
Feb 18
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
244
-0.36%
|
$111,020
$455.06 P/Share
|
|
Feb 18
2025
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,657
-8.6%
|
$753,935
$455.06 P/Share
|
|
Feb 18
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
671
-5.85%
|
$305,305
$455.06 P/Share
|
|
Feb 14
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,139
-2.79%
|
$990,357
$463.46 P/Share
|
|
Feb 14
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,293
-3.26%
|
$1,061,659
$463.46 P/Share
|
|
Feb 14
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,293
-3.5%
|
$1,061,659
$463.46 P/Share
|
|
Feb 14
2025
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,912
-4.46%
|
$885,256
$463.46 P/Share
|
|
Feb 14
2025
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,553
-4.82%
|
$3,034,039
$463.46 P/Share
|
|
Feb 14
2025
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
6,066
-20.16%
|
$2,808,558
$463.46 P/Share
|
|
Feb 14
2025
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,724
-3.52%
|
$1,261,212
$463.46 P/Share
|
|
Feb 14
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,529
-5.19%
|
$707,927
$463.46 P/Share
|
|
Feb 14
2025
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,504
-7.24%
|
$696,352
$463.46 P/Share
|
|
Feb 14
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,293
-4.74%
|
$1,061,659
$463.46 P/Share
|
|
Feb 14
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
564
-4.69%
|
$261,132
$463.46 P/Share
|
|
Feb 13
2025
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,525
-7.74%
|
$1,136,250
$450.83 P/Share
|
|
Feb 12
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,655
+9.22%
|
-
|
|
Feb 12
2025
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
7,209
+18.1%
|
-
|
|
Feb 12
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+8.13%
|
-
|
|
Feb 12
2025
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,437
+17.6%
|
-
|
|
Feb 12
2025
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
5,546
+11.46%
|
-
|
|
Feb 12
2025
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
19,015
+12.27%
|
-
|
|
Feb 12
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+7.48%
|
-
|
|
Feb 12
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,080
+14.74%
|
-
|
|
Feb 12
2025
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
7,903
+9.26%
|
-
|